SG11201407961WA - Risperidone or paliperidone implant formulation - Google Patents

Risperidone or paliperidone implant formulation

Info

Publication number: SG11201407961WA
Authority: SG; Singapore
Prior art keywords: international; madrid; risperidone; julian; paliperidone
Prior art date: 2012-05-31

Application number

SG11201407961WA

Other languages

English (en)

Inventor

Aduriz Ibon Gutierro

Rodríguez Guillermo Franco

Original Assignee

Farmacéuticos Rovi S A Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-31

Filing date

2013-05-31

Publication date

2014-12-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407961W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-31 Application filed by Farmacéuticos Rovi S A Lab filed Critical Farmacéuticos Rovi S A Lab

2014-12-30 Publication of SG11201407961WA publication Critical patent/SG11201407961WA/en

Links

239000000203 mixture Substances 0.000 title abstract 5
PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title abstract 3
239000007943 implant Substances 0.000 title abstract 3
229960001057 paliperidone Drugs 0.000 title abstract 3
229960001534 risperidone Drugs 0.000 title abstract 3
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 title abstract 3
238000009472 formulation Methods 0.000 title abstract 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 3
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
229920001577 copolymer Polymers 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
238000011065 in-situ storage Methods 0.000 abstract 1
238000007918 intramuscular administration Methods 0.000 abstract 1
239000000178 monomer Substances 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000002904 solvent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)

SG11201407961WA 2012-05-31 2013-05-31 Risperidone or paliperidone implant formulation SG11201407961WA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12170362.3A EP2529756B1 (en)	2011-05-31	2012-05-31	Risperidone and/or Paliperidone implant formulation
PCT/EP2013/061320 WO2013178812A1 (en)	2012-05-31	2013-05-31	Risperidone or paliperidone implant formulation

Publications (1)

Publication Number	Publication Date
SG11201407961WA true SG11201407961WA (en)	2014-12-30

Family

ID=46147376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201407961WA SG11201407961WA (en)	2012-05-31	2013-05-31	Risperidone or paliperidone implant formulation

Country Status (32)

Country	Link
EP (2)	EP2529756B1 (sr)
JP (1)	JP6367795B2 (sr)
KR (1)	KR101880716B1 (sr)
CN (1)	CN104363923A (sr)
AU (1)	AU2013269547B2 (sr)
BR (1)	BR112014029209A2 (sr)
CA (1)	CA2874765C (sr)
CL (1)	CL2014003216A1 (sr)
CO (1)	CO7160108A2 (sr)
CY (1)	CY1124369T1 (sr)
DK (2)	DK2529756T3 (sr)
EA (1)	EA031819B1 (sr)
ES (2)	ES2878112T3 (sr)
FI (1)	FI2854858T3 (sr)
HR (2)	HRP20260301T1 (sr)
IL (1)	IL235849B (sr)
IN (1)	IN2014DN10672A (sr)
LT (2)	LT2529756T (sr)
MA (1)	MA37664B1 (sr)
MX (1)	MX374955B (sr)
MY (1)	MY174999A (sr)
NZ (1)	NZ703321A (sr)
PH (1)	PH12014502667B1 (sr)
PL (2)	PL2529756T3 (sr)
PT (2)	PT2529756T (sr)
RS (1)	RS62059B1 (sr)
SG (1)	SG11201407961WA (sr)
SI (2)	SI2529756T1 (sr)
SM (1)	SMT202100448T1 (sr)
UA (1)	UA119430C2 (sr)
WO (1)	WO2013178812A1 (sr)
ZA (1)	ZA201409299B (sr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8852638B2 (en)	2005-09-30	2014-10-07	Durect Corporation	Sustained release small molecule drug formulation
ES2562878T3 (es)	2007-05-25	2016-03-08	Indivior Uk Limited	Formulaciones de liberación sostenida de compuestos de risperidona
US10285936B2 (en)	2010-05-31	2019-05-14	Laboratorios Farmacéuticos Rovi, S.A.	Injectable composition with aromatase inhibitor
US10350159B2 (en)	2010-05-31	2019-07-16	Laboratories Farmacéuticos Rovi, S.A.	Paliperidone implant formulation
US10335366B2 (en)	2010-05-31	2019-07-02	Laboratorios Farmacéuticos Rovi, S.A.	Risperidone or paliperidone implant formulation
US10881605B2 (en)	2010-05-31	2021-01-05	Laboratorios Farmaceuticos Rovi, S.A.	Methods for the preparation of injectable depot compositions
US10463607B2 (en)	2010-05-31	2019-11-05	Laboratorios Farmaceutics Rofi S.A.	Antipsychotic Injectable Depot Composition
PL2394664T3 (pl)	2010-05-31	2016-12-30		Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
PL2394663T3 (pl)	2010-05-31	2022-02-21	Laboratorios Farmaceuticos Rovi, S.A.	Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
PT2529756T (pt) *	2011-05-31	2021-07-28	Farm Rovi Lab Sa	Formulação de implante de risperidona e/ou paliperidona
ES2456917T3 (es) *	2011-05-31	2014-04-24	Laboratorios Farmacéuticos Rovi, S.A.	Formulación de implante de paliperidona
EA033537B1 (ru)	2013-03-11	2019-10-31	Durect Corp	Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
US20140308352A1 (en)	2013-03-11	2014-10-16	Zogenix Inc.	Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) *	2015-06-01	2016-10-26	湖南赛沃药业有限公司	一种利培酮植入剂及其制备方法
CN109589304A (zh) *	2017-10-01	2019-04-09	万特制药(海南)有限公司	利培酮口服溶液及其制备方法
EP3803866A4 (en)	2018-05-24	2022-03-16	Nureva Inc.	METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es)	2018-05-24	2021-04-28	Celanese Eva Performance Polymers Llc	Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
KR20260007295A (ko)	2018-05-24	2026-01-13	셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨	거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
PE20210047A1 (es)	2018-06-12	2021-01-08	Farm Rovi Lab Sa	Composicion inyectable
BR112023022439A2 (pt)	2021-04-26	2023-12-26	Celanese Eva Performance Polymers Llc	Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US12594236B2 (en)	2021-07-16	2026-04-07	Laboratorios Farmaceuticos Rovi, S.A.	Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en)	2021-07-16	2025-06-03	Laboratorios Farmaceuticos Rovi, S.A.	Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh)	2021-09-21	2023-04-01	西班牙商禾霏藥品實驗室有限公司	抗精神病可注射儲積型組合物
CA3248062A1 (en)	2022-05-18	2025-07-10	Laboratorios Farmacéuticos Rovi, S.A.	Extended-release injectable compositions intended for use in treatment with risperidone in conjunction with CYP2D6 enzyme inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1074923C (zh)	1993-11-19	2001-11-21	詹森药业有限公司	微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US7658998B2 (en) *	2003-01-22	2010-02-09	Alkermes Controlled Therapeutics, Inc.	Method of preparing sustained release microparticles
ES2600554T3 (es) *	2003-07-18	2017-02-09	Oakwood Laboratories L.L.C.	Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
BRPI0513089B8 (pt)	2004-08-04	2021-05-25	Alza Corp	forma de dosagem para liberação controlada de um fármaco de ordem ascendente de zero
BRPI0809837A2 (pt)	2007-04-19	2014-11-11	Youxin Li	"composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
EP2167039B1 (en) *	2007-05-18	2016-09-28	Durect Corporation	Improved depot formulations
ES2562878T3 (es) *	2007-05-25	2016-03-08	Indivior Uk Limited	Formulaciones de liberación sostenida de compuestos de risperidona
WO2009015828A1 (en)	2007-07-27	2009-02-05	Synthon B.V.	Paliperidone derivatives
KR102318070B1 (ko)	2007-12-19	2021-10-27	얀센 파마슈티카 엔.브이.	장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
WO2011042453A1 (en)	2009-10-06	2011-04-14	Ascendis Pharma As	Subcutaneous paliperidone composition
PL2394664T3 (pl) *	2010-05-31	2016-12-30		Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
PL2394663T3 (pl) *	2010-05-31	2022-02-21	Laboratorios Farmaceuticos Rovi, S.A.	Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
PT2529756T (pt) *	2011-05-31	2021-07-28	Farm Rovi Lab Sa	Formulação de implante de risperidona e/ou paliperidona
ES2456917T3 (es) *	2011-05-31	2014-04-24	Laboratorios Farmacéuticos Rovi, S.A.	Formulación de implante de paliperidona

2012
- 2012-05-31 PT PT121703623T patent/PT2529756T/pt unknown
- 2012-05-31 EP EP12170362.3A patent/EP2529756B1/en active Active
- 2012-05-31 LT LTEP12170362.3T patent/LT2529756T/lt unknown
- 2012-05-31 RS RS20210834A patent/RS62059B1/sr unknown
- 2012-05-31 SM SM20210448T patent/SMT202100448T1/it unknown
- 2012-05-31 DK DK12170362.3T patent/DK2529756T3/da active
- 2012-05-31 PL PL12170362T patent/PL2529756T3/pl unknown
- 2012-05-31 SI SI201231933T patent/SI2529756T1/sl unknown
- 2012-05-31 ES ES12170362T patent/ES2878112T3/es active Active
2013
- 2013-05-31 CN CN201380027927.8A patent/CN104363923A/zh active Pending
- 2013-05-31 EA EA201401346A patent/EA031819B1/ru unknown
- 2013-05-31 IN IN10672DEN2014 patent/IN2014DN10672A/en unknown
- 2013-05-31 KR KR1020147035300A patent/KR101880716B1/ko active Active
- 2013-05-31 UA UAA201414187A patent/UA119430C2/uk unknown
- 2013-05-31 AU AU2013269547A patent/AU2013269547B2/en active Active
- 2013-05-31 CA CA2874765A patent/CA2874765C/en active Active
- 2013-05-31 EP EP13726003.0A patent/EP2854858B1/en active Active
- 2013-05-31 HR HRP20260301TT patent/HRP20260301T1/hr unknown
- 2013-05-31 MX MX2014014483A patent/MX374955B/es active IP Right Grant
- 2013-05-31 JP JP2015514533A patent/JP6367795B2/ja active Active
- 2013-05-31 MY MYPI2014703551A patent/MY174999A/en unknown
- 2013-05-31 NZ NZ703321A patent/NZ703321A/en unknown
- 2013-05-31 BR BR112014029209A patent/BR112014029209A2/pt not_active Application Discontinuation
- 2013-05-31 FI FIEP13726003.0T patent/FI2854858T3/fi active
- 2013-05-31 SI SI201332120T patent/SI2854858T1/sl unknown
- 2013-05-31 DK DK13726003.0T patent/DK2854858T3/da active
- 2013-05-31 ES ES13726003T patent/ES3064200T3/es active Active
- 2013-05-31 PL PL13726003.0T patent/PL2854858T3/pl unknown
- 2013-05-31 LT LTEPPCT/EP2013/061320T patent/LT2854858T/lt unknown
- 2013-05-31 WO PCT/EP2013/061320 patent/WO2013178812A1/en not_active Ceased
- 2013-05-31 PT PT137260030T patent/PT2854858T/pt unknown
- 2013-05-31 SG SG11201407961WA patent/SG11201407961WA/en unknown
2014
- 2014-11-23 IL IL235849A patent/IL235849B/en active IP Right Grant
- 2014-11-26 CL CL2014003216A patent/CL2014003216A1/es unknown
- 2014-11-28 PH PH12014502667A patent/PH12014502667B1/en unknown
- 2014-12-16 MA MA37664A patent/MA37664B1/fr unknown
- 2014-12-17 ZA ZA2014/09299A patent/ZA201409299B/en unknown
- 2014-12-30 CO CO14285844A patent/CO7160108A2/es unknown
2021
- 2021-07-02 HR HRP20211057TT patent/HRP20211057T1/hr unknown
- 2021-07-16 CY CY20211100644T patent/CY1124369T1/el unknown

Also Published As

Publication number	Publication date
CN104363923A (zh)	2015-02-18
JP6367795B2 (ja)	2018-08-01
LT2529756T (lt)	2021-07-26
CA2874765A1 (en)	2013-12-05
CO7160108A2 (es)	2015-01-15
EP2854858B1 (en)	2025-12-10
IN2014DN10672A (sr)	2015-08-28
PL2529756T3 (pl)	2021-11-15
PH12014502667B1 (en)	2020-01-22
AU2013269547B2 (en)	2018-03-15
PT2854858T (pt)	2026-03-06
IL235849B (en)	2019-03-31
WO2013178812A1 (en)	2013-12-05
KR101880716B1 (ko)	2018-08-17
ZA201409299B (en)	2015-12-23
SI2529756T1 (sl)	2021-09-30
EP2529756A2 (en)	2012-12-05
BR112014029209A2 (pt)	2017-06-27
HRP20211057T1 (hr)	2021-10-01
FI2854858T3 (fi)	2026-03-03
ES3064200T3 (en)	2026-04-23
HRP20260301T1 (hr)	2026-04-10
CY1124369T1 (el)	2022-07-22
RS62059B1 (sr)	2021-07-30
EA031819B1 (ru)	2019-02-28
MA37664B1 (fr)	2016-11-30
DK2854858T3 (da)	2026-03-09
KR20150016964A (ko)	2015-02-13
EA201401346A1 (ru)	2015-04-30
PL2854858T3 (pl)	2026-04-20
EP2529756A3 (en)	2013-08-07
PT2529756T (pt)	2021-07-28
IL235849A0 (en)	2015-01-29
EP2529756B1 (en)	2021-05-19
EP2854858A1 (en)	2015-04-08
PH12014502667A1 (en)	2015-02-02
NZ703321A (en)	2017-01-27
CA2874765C (en)	2020-06-02
SMT202100448T1 (it)	2021-09-14
ES2878112T3 (es)	2021-11-18
SI2854858T1 (sl)	2026-04-30
AU2013269547A1 (en)	2015-01-22
MX374955B (es)	2025-03-06
CL2014003216A1 (es)	2015-07-10
JP2015518036A (ja)	2015-06-25
MY174999A (en)	2020-06-01
LT2854858T (lt)	2026-03-10
MA37664A1 (fr)	2016-03-31
MX2014014483A (es)	2015-02-24
DK2529756T3 (da)	2021-08-02
UA119430C2 (uk)	2019-06-25

Publication	Publication Date	Title
SG11201407961WA (en)	2014-12-30	Risperidone or paliperidone implant formulation
SG11201407971QA (en)	2014-12-30	Paliperidone implant formulation
SG11201901141WA (en)	2019-03-28	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
SG11201907604UA (en)	2019-09-27	Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201906431UA (en)	2019-08-27	Method for the treatment of thromboembolism
SG11201901534VA (en)	2019-03-28	Combination therapy with controlled-release cnp agonists
SG11201908740VA (en)	2019-11-28	Sustained release delivery systems comprising traceless linkers
SG11201907804QA (en)	2019-09-27	Pharmaceutical composition comprising selexipag
SG11201908330PA (en)	2019-10-30	Farnesoid x receptor agonists and uses thereof
SG11201903946SA (en)	2019-05-30	Devices and methods for slurry generation
SG11201811470PA (en)	2019-01-30	Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201807185UA (en)	2018-09-27	Modified hyaluronic acid, method for making same and uses thereof
SG11201805570WA (en)	2018-07-30	Systems and methods for long term transdermal administration
SG11201909303TA (en)	2019-11-28	Point of delivery cold slurry generation
SG11201407397WA (en)	2014-12-30	Formulations and methods for vaginal delivery of antiprogestins
SG11201807977XA (en)	2018-10-30	Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
SG11201906958TA (en)	2019-08-27	Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201811209QA (en)	2019-01-30	Oral gastroretentive formulations and uses thereof
SG11201906436VA (en)	2019-08-27	Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201811580SA (en)	2019-01-30	Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201906959RA (en)	2019-08-27	Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201408240TA (en)	2015-01-29	Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201407368VA (en)	2015-01-29	Drug for preventing and/or treating polycystic kidney disease
SG11201908691PA (en)	2019-10-30	Compounds and methods for the treatment of parasitic diseases
SG11201901249YA (en)	2019-04-29	Aza-indazole compounds for use in tendon and/or ligament injuries